---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-010602"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2026-03-17T23:59:59+00:00"
generated_at: "2026-05-15T10:24:46.920271+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement

## Summary
- ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.
- No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.
- Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.
- Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange.

## SEC filing metadata
- accession: 0001493152-26-010602
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2026-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/0001493152-26-010602-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-010602
- JSON: https://secwatch.observer/filing/0001493152-26-010602.json
- Plain text: https://secwatch.observer/filing/0001493152-26-010602.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.